-The Indian Express As the government begins the second phase of rollout of Direct Benefits Transfer in 78 districts from July 1, it would do well to look back at the rather shaky experience of the scheme's implementation in the past six months, and whether it is in fact prepared to bring in more areas under the scheme's ambit. The ambitious plan, that aims at eliminating middlemen and ensuring money reaches beneficiaries...

-The Hindu Whichever way one looks at the data, there is nothing much to crow about the 68th round of survey Whichever way one looks at the key indicators of employment and unemployment released by the National Sample Survey Office (NSSO) recently, there is nothing much to crow about in inferences that can be drawn from the data collected in the 68th round of survey conducted during the period July 2011 to...

-The Hindu     The national culture of unquestioned obedience to authority along with an acceptance of shoddiness must not be used as an excuse to overlook violations of corporate ethics, says the Ranbaxy whistle-blower During my tenure at Ranbaxy, I was surprised by the unchallenged conformity to the poor decisions of senior leadership. Ranbaxy was my first Indian employer following my tenure at two different American corporations. Reflecting on this experience from cultural...

-The Business Standard Time to question the assumptions behind the food Bill In the midst of all the politicking as to how and when the draft food security Bill will become law, one thing at least is clear: the United Progressive Alliance (UPA) intends to push forward with the much-criticised legislation. UPA-II has little to show for four years in power, and perhaps it imagines that the Bill will somehow alter the...

-The Business Standard Govt should streamline its free medicines plan The Centre is reportedly going to shelve a plan to procure generic drugs for free supply to patients throughout the country. This is a serious error. Reportedly, states will instead be asked to do so; but, if a perceived inability to procure, stock and distribute these drugs is the reason for backtracking on the plan, how precisely will states be free of...